Literature DB >> 3276906

Occurrence of bacteremia during and after hemorrhagic shock.

J M Koziol1, B F Rush, S M Smith, G W Machiedo.   

Abstract

In recent research, hemorrhagic shock and septic shock have been studied as two separate entities. We have developed a treated model of hemorrhagic shock in which unrestrained and unanesthetized rats are bled to a mean arterial pressure of 30 torr until 80% of the maximum shed volume must be returned. Rats are maintained preshock and treated post shock with a 20% glucose-electrolyte solution. Survival of these animals is 62% at 24 hours post shock and all animals are dead at 72 hours post shock. Blood cultures obtained during shock become positive at 2 hours into the shock period and are significant compared to controls at 3 to 5 hours of shock (p less than 0.0001). Blood cultures obtained after the period of shock are significantly positive at 24 and 48 hours post shock (p less than 0.05) compared to controls. Intrashock cultures are monomicrobial; the majority of post-shock cultures are polymicrobial. All cultured organisms are normal rat enteric flora. Histologic changes of renal failure are also demonstrated post shock. We suggest that bacterial invasion, possibly from the gut, plays a role in the sepsis seen in patients following severe hemorrhagic shock. Sepsis may precede rather than follow the immune incompetence which accompanies shock.

Entities:  

Mesh:

Year:  1988        PMID: 3276906

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  15 in total

1.  Induction of a rat enteric defensin gene by hemorrhagic shock.

Authors:  M R Condon; A Viera; M D'Alessio; G Diamond
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

Review 2.  The relationship between gut-derived bacteria and the development of the multiple organ dysfunction syndrome.

Authors:  G A Nieuwenhuijzen; E A Deitch; R J Goris
Journal:  J Anat       Date:  1996-12       Impact factor: 2.610

3.  Neutrophils counteract autophagy-mediated anti-inflammatory mechanisms in alveolar macrophage: role in posthemorrhagic shock acute lung inflammation.

Authors:  Zongmei Wen; Liyan Fan; Yuehua Li; Zui Zou; Melanie J Scott; Guozhi Xiao; Song Li; Timothy R Billiar; Mark A Wilson; Xueyin Shi; Jie Fan
Journal:  J Immunol       Date:  2014-09-29       Impact factor: 5.422

4.  Organ distribution of radiolabeled enteric Escherichia coli during and after hemorrhagic shock.

Authors:  J A Redan; B F Rush; J N McCullough; G W Machiedo; T F Murphy; G S Dikdan; S Smith
Journal:  Ann Surg       Date:  1990-06       Impact factor: 12.969

Review 5.  The role of gut mucosal hypoperfusion in the pathogenesis of post-operative organ dysfunction.

Authors:  M G Mythen; A R Webb
Journal:  Intensive Care Med       Date:  1994       Impact factor: 17.440

6.  The effect of hypoxia on permeability and bacterial translocation in Caco-2 adult and I-407 fetal enterocyte cell culture models.

Authors:  Y Tazuke; R A Drongowski; D H Teitelbaum; A G Coran
Journal:  Pediatr Surg Int       Date:  2003-05-06       Impact factor: 1.827

7.  Endotoxemia and bacteremia during hemorrhagic shock. The link between trauma and sepsis?

Authors:  B F Rush; A J Sori; T F Murphy; S Smith; J J Flanagan; G W Machiedo
Journal:  Ann Surg       Date:  1988-05       Impact factor: 12.969

8.  Intra-operative gut mucosal hypoperfusion is associated with increased post-operative complications and cost.

Authors:  M G Mythen; A R Webb
Journal:  Intensive Care Med       Date:  1994       Impact factor: 17.440

9.  Surgical manipulation of the intestine results in quantitative and qualitative alterations in luminal Escherichia coli.

Authors:  Simmy Thomas; Gagandeep Kang; Kunissery A Balasubramanian
Journal:  Ann Surg       Date:  2004-08       Impact factor: 12.969

10.  Composition and diversity of intestinal coliform flora influence bacterial translocation in rats after hemorrhagic stress.

Authors:  M Katouli; T Bark; O Ljungqvist; T Svenberg; R Möllby
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.